We are encouraged by the FDA’s action. Originally, BRI sought orphan drug designation for ANP in optic pathway glioma in kids, a very much narrower indication regarding a smaller segment of tumors, said Dr. Stanislaw R. Burzynski, M.D., Ph.D. Nevertheless, the FDA prolonged orphan drug designation to all or any gliomas, a recognition we believe underlies the broad potential of anitneoplaston therapy for the treatment of patients with malignancy of the mind and nervous system. There is now even more motivation for us to judge our therapy as an innovative and efficacious choice in cure spectrum where disease administration options are still quite limited.Current biopsy techniques require physicians to consider many random cells samples, and for a few disorders of the colon, these procedures can be disfiguring and life-changing. Rather than taking tissue samples, the brand new system would aim brief bursts of light from the end of an endoscope at locations suspected of having disease. When light can be directed at these tissues, it scatters, said Adam Wax, Theodroe Kennedy associate professor of biomedical engineering at Duke’s Pratt School of Engineering, who developed the device. The results of the Duke team’s preliminary experiments were reported on-line in the Journal of Biomedical Optics.